Please ensure Javascript is enabled for purposes of website accessibility

Will Stryker's Acquisition Spree Strike It Rich?

By Dan Carroll – Feb 24, 2014 at 2:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Stryker's pushing hard for mergers and acquisitions to expand its reach both at home and across the globe, but will this pay off for eager investors?

Orthopedics giant Stryker's (SYK 0.97%) impressed Wall Street in the early part of 2014, but this company is looking ahead to more than just the good feelings from its latest earnings report. Stryker is interested in growth -- and it is looking to buy its way to better results by snapping up small and innovative firms that can give it a leg up on its competition.

Stryker made waves last year when it acquired robotic surgery maker MAKO Surgical, and 2014's only brought more of a buying bonanza from this medical device giant. This past week, Stryker hit the headlines again by picking up German surgical tools firm Berchtold Holdings, a move it expects to boost its fast-growing endoscopy division. It's a much smaller deal than the MAKO buy, especially for a company of Stryker's size, with a market cap of more than $30 billion. But the acquisition of Berchtold gives a big boost to one of Stryker's under-the-radar growth drivers in endoscopy and highlights the company's M&A focus, something that's likely to dominate this company's news in the coming year.

Will Stryker's acquisitions drive reward investors, though? Motley Fool contributor Dan Carroll tells you what to expect from this company's latest buy -- and how Stryker's future could help the leading medical device stock surge.

Dan Carroll has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Stocks Mentioned

Stryker Stock Quote
$243.11 (0.97%) $2.34
Boston Scientific Stock Quote
Boston Scientific
$46.60 (1.04%) $0.48
Smith & Nephew plc Stock Quote
Smith & Nephew plc
$27.18 (1.80%) $0.48

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.